

1 **Comparison of the reactogenicity and immunogenicity between two-dose mRNA**  
2 **COVID-19 vaccine and inactivated followed by an mRNA vaccine in children aged 5 -**  
3 **11 years**

4 Nasamon Wanlapakorn<sup>a#</sup>, Sitthichai Kanokudom<sup>a,b#</sup>, Harit Phowatthanasathian<sup>c</sup>, Jira  
5 Chansaenroj<sup>a</sup>, Nungruthai Suntronwong<sup>a</sup>, Suvichada Assawakosri<sup>a,b</sup>, Ritthideach Yorsaeng  
6<sup>a</sup>, Pornjarim Nilyanimit<sup>a</sup>, Preeyaporn Vichaiwattana<sup>a</sup>, Sirapa Klinfueng<sup>a</sup>, Thanunrat  
7 Thongmee<sup>a</sup>, Ratchadawan Aeemjinda<sup>a</sup>, Nongkanok Khanarat<sup>a</sup>, Donchida Srimuan<sup>a</sup>,  
8 Thaksaporn Thatsanatorn<sup>a</sup>, Natthinee Sudhinaraset<sup>a</sup>, and Yong Poovorawan<sup>a,d\*</sup>

9<sup>a</sup> Center of Excellence in Clinical Virology, Department of Pediatrics, Faculty of Medicine,  
10 Chulalongkorn University, Bangkok, 10330, Thailand.

11<sup>b</sup> Center of Excellence in Osteoarthritis and Musculoskeleton, Faculty of Medicine,  
12 Chulalongkorn University, King Chulalongkorn Memorial Hospital, Thai Red Cross Society,  
13 Bangkok, 10330, Thailand.

14<sup>c</sup> Chulalongkorn University International Medical Program (CU-MEDi), Faculty of Medicine,  
15 Chulalongkorn University, Bangkok, Thailand.

16<sup>d</sup> FRS(T), the Royal Society of Thailand, Sanam Sueapa, Dusit, Bangkok, 10300, Thailand.

17 #These two authors equally contribute to the study.

18 \*Corresponding authors: Yong Poovorawan (yong.p@chula.ac.th).

19 **Running head:** Homologous and heterologous COVID-19 vaccine in children

20

21 **Abstract**

22 **Objective:** To compare the reactogenicity and immunogenicity between the two-dose mRNA  
23 COVID-19 vaccine regimen and one or two doses of inactivated vaccine followed by an  
24 mRNA vaccine regimen in healthy children between 5-11 years of age.

25 **Methods:** A prospective cohort study was performed at King Chulalongkorn Memorial  
26 Hospital in Thailand between March to June 2022. Healthy children between 5-11 years of  
27 age were enrolled and received the two-dose mRNA COVID-19 vaccine (BNT162b2)  
28 regimen or the inactivated (CoronaVac) vaccine followed by the BNT162b2 vaccine regimen.  
29 In addition, healthy children who received two doses of BBIBP-CorV between 1-3 months  
30 prior were enrolled to receive a heterologous BNT162b2 as a third dose (booster).  
31 Reactogenicity was assessed by a self-reported online questionnaire. Immunogenicity  
32 analysis was performed to determine binding and surrogate neutralizing antibodies to SARS-  
33 CoV-2 wild-type and Omicron variants.

34 **Results:** Overall, 166 eligible children were enrolled. Local and systemic AE which occurred  
35 within 7 days after vaccination were mild to moderate and well-tolerated. At one-month,  
36 post-two or post-three doses, children vaccinated with two-dose BNT162b2,  
37 CoronaVac/BNT162b2, and two-dose BBIBP-CorV followed by BNT162b2 elicited similar  
38 levels of anti-receptor-binding domain (RBD) IgG. However, the two-dose BNT162b2 and  
39 two-dose BBIBP-CorV followed by BNT162b2 groups elicited higher neutralizing activities  
40 against Omicron BA.2 variant than the CoronaVac/BNT162b2 group.

41 **Conclusion:** The heterologous, CoronaVac vaccine followed by the BNT162b2 vaccine,  
42 regimen elicited lower neutralizing activities against the emerging Omicron BA.2 variant  
43 than the two-dose mRNA regimen. A third dose (booster) mRNA vaccine should be  
44 prioritized for this group.

- 45 **Keywords:** Severe acute respiratory virus 2 (SARS-CoV-2); Omicron; mRNA; inactivated;
- 46 vaccine; booster

## 47 1. Introduction

48 The COVID-19 pandemic, caused by SARS-CoV-2, has caused more than 600  
49 million infections and more than 6.5 million deaths worldwide as of October 2022.<sup>1</sup> The first  
50 COVID-19 vaccine that received emergency use authorization from the United States Food  
51 and Drug Administration (FDA) in December 2020 was the BNT162b2 vaccine for persons  
52 16 years of age or older.<sup>2,3</sup> Later on, several effective COVID-19 vaccines were developed,  
53 tested, and initially distributed to the adult population, leaving children as a vulnerable  
54 population.

55 During the early COVID-19 pandemic, children infected with SARS-CoV-2 often  
56 developed mild symptoms.<sup>4</sup> Nevertheless, the increase of symptomatic SARS-CoV-2  
57 infection and hospitalization rate among children during the Delta (B.1.617.2) and Omicron  
58 (B.1.1.529) variants era indicated the need to extend vaccination to the pediatric population.  
59 Between October to December 2020, a phase 1/2 randomized controlled trial to assess the  
60 safety and immunogenicity of the inactivated CoronaVac vaccine in children between 3-17  
61 years was conducted in China.<sup>5</sup> The results showed that 3.0 µg CoronaVac was safe and able  
62 to elicit 100% seroconversion in children. In addition, another randomized controlled trial in  
63 2020 demonstrated that the 4.0 µg inactivated BBIBP-CorV vaccine was safe for children 3-  
64 18 years and could elicit a robust humoral response after two doses.<sup>6</sup>

65 Apart from the inactivated vaccine, an mRNA vaccine has also been extended to the  
66 pediatric population. On October 29, 2021, the BNT162b2 vaccine was approved as an  
67 emergency use authorization for children 5-to-11-years old in the US based on the data in  
68 phase 2/3 trial which demonstrated that two doses of the 10 µg BNT162b2 vaccine  
69 administered 21 days apart showed an efficacy of 90.7% against the circulating SARS-CoV-2  
70 variant.<sup>2</sup> In December 2021, the Centers for Disease Control and Prevention (CDC) reviewed  
71 adverse events of the BNT162b2 vaccine from the Vaccine Adverse Event Reporting System

72 (VAERS) and reported that myocarditis was associated with the mRNA-based COVID-19  
73 vaccine.<sup>7</sup> This rare but serious side effect raised concerns among the parents which could lead  
74 to vaccine hesitancy.

75 Thailand has secured the inactivated CoronaVac vaccine since February 2021, the  
76 inactivated BBIBP-CorV vaccine since June 2021, and the mRNA BNT162b2 vaccine since  
77 August 2021. In December 2021, the BNT162b2 vaccine was approved by the Thai FDA as a  
78 two-dose regimen for children aged between 5-11 years. In February 2022, the two-dose  
79 CoronaVac and two-dose BBIBP-CorV vaccines were approved by the Thai FDA for  
80 children aged between 6-11 years. The Ministry of Public Health and the Royal College of  
81 Thai Pediatricians recommended a dosing interval of 8 weeks for the two-dose BNT162b2  
82 regimen based on an immunogenicity study reporting that a long-interval vaccination  
83 schedule induced higher antibody response compared to a short-interval vaccination  
84 schedule.<sup>8</sup> Besides, the Ministry of Public Health and the Royal College of Thai  
85 Pediatricians also recommended that a heterologous inactivated (CoronaVac) vaccine  
86 followed by the BNT162b2 vaccine administered 4 weeks apart could be an alternative  
87 regimen for parents concerned about the adverse events following an mRNA vaccination.  
88 Our previous immunogenicity study in Thai healthy adults vaccinated with a heterologous,  
89 CoronaVac vaccine followed by the BNT162b2 vaccine regimen showed that this regimen  
90 induced a higher antibody response compared to the homologous CoronaVac.<sup>9</sup>

91 Amidst the emergence of the Omicron variant, both two-dose mRNA or inactivated  
92 vaccination regimens cannot prevent breakthrough infections.<sup>10, 11</sup> A third dose is  
93 recommended to obtain high immunity against the Omicron variant. Our previous studies in  
94 adults have shown that a booster mRNA vaccine after inactivated (CoronaVac or BBIBP-  
95 CorV)-primed individuals elicited a high level of antibody responses against the Omicron

96 variant.<sup>12, 13</sup> However, there was limited information about the safety and immunogenicity of  
97 a heterologous mRNA booster in inactivated vaccine-primed children.

98         This study aims to compare the reactogenicity and immunogenicity between the  
99 heterologous CoronaVac vaccine followed by the BNT162b2 vaccine regimen and the two-  
100 dose BNT162b2 vaccine regimen in children between 5-11 years of age. In addition, the  
101 reactogenicity and immunogenicity of the heterologous BNT162b2 booster in BBIBP-CorV-  
102 primed children were evaluated. The results of this study will help guide the physician's  
103 decision on a mix-and-match vaccine strategy in certain circumstances and guide the booster  
104 strategy in the two-dose BBIBP-CorV-primed children.

105

## 106 **2. Materials and methods**

### 107 **2.1. Study design and participants**

108         This prospective cohort study was conducted between March to June 2022 at the  
109 clinical trial research unit at the Center of Excellence in Clinical Virology, Department of  
110 Pediatrics, Faculty of Medicine, Chulalongkorn University in Bangkok, Thailand. The study  
111 protocol was approved by the Institutional Review Board (IRB) of the Faculty of Medicine of  
112 Chulalongkorn University (IRB 059/65) and was performed under the principles of the  
113 Declaration of Helsinki. This trial was registered in the Thai Clinical Trials Registry  
114 (TCTR20220212001). Written informed consent was obtained from the parents or the legal  
115 guardians of participants prior to enrollment. Written assent was obtained from children aged  
116 7 years and above. The inclusion criteria were immunocompetent children between 5-11 of  
117 age with no or well-controlled underlying diseases, no previous COVID-19 vaccination, and  
118 no previous SARS-CoV-2 infection from the medical history. The first group of participants  
119 was enrolled to receive the two-dose BNT162b2 regimen administered 8 weeks apart. The  
120 second group was enrolled to receive the CoronaVac followed by BNT162b2 vaccination

121 administered 4 weeks apart. In addition, the third group of participants who had previously  
122 been immunized with two doses of the BBIBP-CorV vaccine between 1-3 months prior were  
123 enrolled. Participants received two doses of the BBIBP-CorV vaccine in other hospitals but  
124 need to provide immunization records in the electronic health record from the Ministry of  
125 Public health, Thailand prior to enrollment. This group is consented to receiving the third  
126 dose (booster) with BNT162b2. The inclusion criteria are the same as in the CoronaVac  
127 followed by BNT162b2 and homologous two-dose BNT162b2 groups, except the criteria of  
128 no previous COVID-19 vaccination.

## 129 **2.2. Vaccine and blood collection**

130 The CoronaVac vaccine from Sinovac Life Sciences, Beijing, China (hereafter  
131 referred to as SV) is an inactivated SARS-CoV-2 vaccine (CZ02 strain). The dosage for the  
132 pediatric population is 0.5 mL per dose containing 600 Spike Units (equal to 3 micrograms)  
133 of inactivated SARS-CoV-2 whole virus as antigen. The BBIBP-CorV vaccine from  
134 Sinopharm, Beijing, China (hereafter referred to as SP) is also an inactivated vaccine  
135 developed from the whole SARS-CoV-2 stain HB02. The interval recommended for the SP  
136 vaccine is two doses administered 4 weeks apart. The BNT162b2 from Pfizer-BioNTech,  
137 NY, USA (hereafter referred to as PF) is a lipid nanoparticle containing mRNA encoding the  
138 SARS-CoV-2 full-length spike of ancestral SARS-CoV-2 strain. The dosage for the pediatric  
139 population is 0.2 mL (10 micrograms) per dose. The recommended interval for SV/PF and  
140 PF/PF regimens are 4 and 8 weeks, respectively.

141 For participants in the SV/PF and PF/PF groups, blood samples were collected before  
142 the first dose vaccination (V1, baseline or pre-dose 1), before the second dose vaccination  
143 (V2, pre-dose 2), and one month after the second dose vaccination (V3, post-dose 2).

144 For participants in the SP/SP/PF group, blood samples were collected between 1-3  
145 months after the second dose vaccination (V3, post-dose 2) and one month after the third  
146 dose vaccination (V4, post-dose 3).

### 147 **2.3. Safety assessments**

148 Parents or guardians of the participants recorded both local and systemic adverse  
149 events (AEs) after immunization within 7 days using self-administered online and paper  
150 questionnaires. An explanation of data collection was given to participants by trained  
151 investigators during the vaccination visit. Local and systemic AEs were classified as mild,  
152 moderate, and severe as previously described.<sup>14</sup>

### 153 **2.4. Laboratory assessments**

154 Serum samples were tested for binding antibody specific to the receptor-binding  
155 domain (RBD) of SARS-CoV-2, including total RBD immunoglobulin (Ig) and anti-RBD  
156 IgG, and anti-nucleocapsid (N) IgG as previously described.<sup>15</sup> Neutralizing activities against  
157 wild-type (Euroimmun, Lubeck, Germany) and Omicron (BA.2) (GenScript Biotech, NJ,  
158 USA) were analyzed using a surrogate virus neutralization test (sVNT) as previously  
159 described.<sup>16</sup> The seropositivity of sVNTs against wild-type and Omicron (BA.2) were  
160 determined as  $\geq 35\%$  and  $\geq 30\%$  inhibition, respectively. Samples were tested at the end of the  
161 study using the same batch of test kits.

### 162 **2.5. Statistical analysis**

163 The statistical differences in age between groups were performed using the Kruskal-  
164 Wallis test, followed by Dunn's post hoc test with Bonferroni correction. Local and systemic  
165 adverse events between different regimens after the first and second doses were compared by  
166 risk differences with a 95% confidence interval (CI). Total RBD Ig and anti-RBD IgG were  
167 presented as geometric mean titers (GMT) with a 95% CI. Percent inhibitions by the sVNT



168 assay were presented as a median with interquartile ranges (IQR). Differences in the  
169 geometric mean ratio (GMR) of total RBD Ig and anti-RBD IgG between groups were  
170 calculated by ANCOVA with Bonferroni's adjustment. Differences in percentages of  
171 inhibition between groups were calculated by the Kruskal-Wallis test with Dunn's multiple  
172 comparisons. A  $p$ -value of  $<0.05$  was considered statistically significant.

### 173 **3. Results**

#### 174 **3.1 Demographic data and baseline characteristics**

175 From March to June 2022, a total of 166 children were enrolled in the study. The  
176 consort flow diagram of study participants was shown in Figure 1. There were 43 eligible  
177 participants enrolled in SV/PF group. Among this group, there were 3 participants tested  
178 positive for COVID-19 after the first or second dose vaccination (breakthrough infection), 11  
179 participants who had anti-N IgG, total RBD IgG, or anti-RBD IgG positive at baseline,  
180 presumably due to asymptomatic COVID-19 infection, and 2 participants who had evidence  
181 of SARS-CoV-2 infection as determined by anti-N IgG seroconversion. Therefore, a total of  
182 16 participants in the SV/PF groups were excluded from the final immunogenicity analysis.

183 There were 62 eligible participants enrolled in PF/PF group. Among this group, there  
184 were 11 and 1 participant(s) tested positive for COVID-19 after the first and second dose  
185 vaccination, respectively (breakthrough infection), 3 participants who had anti-N IgG, total  
186 RBD IgG, or anti-RBD IgG positive at baseline, presumably due to asymptomatic COVID-19  
187 infection, 12 participants who had evidence of SARS-CoV-2 infection as determined by anti-  
188 N IgG seroconversion, and 5 participants were lost to follow-up. Therefore, a total of 32  
189 participants in the PF/PF groups were excluded from the final immunogenicity analysis.  
190 There was 1 participant who skipped visit 2, received PF at a local hospital, and returned for  
191 blood testing on visit 3.

192 There were 61 eligible participants enrolled in SP/SP/PF group. Among this group,  
193 there was 1 participant who tested positive for COVID-19 after the third dose of vaccination,  
194 1 participant who had evidence of SARS-CoV-2 infection as determined by anti-N IgG  
195 seroconversion, and 3 participants who were lost to follow-up. Therefore, a total of 5  
196 participants in the SP/SP/PF group were excluded for the final immunogenicity analysis.

197 The demographics and characteristics of the participants are shown in Table 1. There  
198 were 27, 30, and 56 participants in the SV/PF, PF/PF, and SP/SP/PF groups who were  
199 included in the final immunogenicity analysis, respectively. The number of female  
200 participants per total (%) participants were similar among groups. Nevertheless, there was a  
201 statistically significant difference in age between the PF/PF group (mean 6.2 years) and  
202 SP/SP/PF group (mean 7.8 years) (P-value <0.001). The mean interval between doses 1 and 2  
203 were 30.2, 57.4, and 22.9 days in the SV/PF, PF/PF, and SP/SP/PF groups, respectively. The  
204 mean interval between doses 2 and 3 was 61.0 days in the SP/SP/PF group.

205 We also compared the antibody responses elicited by the different vaccine regimens  
206 with those elicited by vaccine regimens plus natural infection (hybrid immunity). Hybrid  
207 immunity groups refer to participants who had anti-N IgG seroconversion after receiving the  
208 vaccine or participants who had pre-existing antibodies (anti-N IgG or total RBD IgG) at  
209 baseline before the first vaccine as described in Table 1.

### 210 **3.2 Safety and reactogenicity profile**

211 The most common solicited local adverse reaction (AE) after vaccination was pain at  
212 the injection site: SV/PF group (first dose 62.5%; second dose 68.6%), PF/PF group (first  
213 dose 59.3%; second dose 57.8%), SP/SP/PF group (third dose; 85.2%). The most common  
214 systemic AE was myalgia (20.0-28.6%) (Figure S1). Comparisons of AEs between SV/PF  
215 and PF/PF regimens after the first or second dose vaccination showed no significant

216 differences in any of the local or systemic AEs (Figure 2). Most of the solicited local and  
217 systemic AEs were mild (grade 1) or moderate (grade 2) and resolved within a few days post-  
218 vaccination (Figure S1). Frequencies of grade 3 local or systemic AEs after ranged between  
219 1% to 3%. No serious AEs were reported.

### 220 **3.3 Total RBD Ig and anti-RBD IgG responses in pediatric participants after different** 221 **regimens of COVID-19 vaccines.**

222 The geometric mean titer (GMT) of total RBD immunoglobulin (Ig) which  
223 predominantly included IgG, but also some amount of IgM and IgA, and anti-RBD IgG were  
224 compared among groups vaccinated with different regimens using ANCOVA with  
225 Bonferroni's adjustment as shown in Figure 3. There were no differences in total RBD Ig and  
226 anti-RBD IgG at pre-vaccination among the SV/PF and PF/PF groups at pre-dose 1 (V1). At  
227 one-month post-dose 2 (V3), the PF/PF group had significantly higher total RBD Ig than the  
228 SV/PF group (Fig 3A) (geometric mean ratio (GMR) 2.04). However, there were no  
229 differences in anti-RBD IgG levels among the SV/PF and PF/PF groups (Fig 3B). In addition,  
230 the three-dose SP/SP/PF group also possessed higher total RBD Ig than the two-dose SV/PF  
231 and PF/PF groups (GMR 3.09 and 1.52, respectively), but there was no difference in the anti-  
232 RBD IgG levels among all groups.

### 233 **3.4 Total RBD Ig and anti-RBD IgG responses between two-dose vaccination and** 234 **hybrid immunity**

235 There was a subgroup of participants (n=11) in the SV/PF group found to have a pre-  
236 existing anti-N IgG, total RBD IgG, or anti-RBD IgG at baseline (before receiving the first  
237 dose SV). The baseline characteristics of this subgroup was shown in Table 1. This group  
238 was excluded from the immunogenicity analysis as they presumably had asymptomatic or  
239 unrecognized COVID-19 infection prior to enrollment. However, all the immunogenicity

240 results were available at the end of the study and children in this group had received the two-  
241 dose SV/PF vaccine. Therefore, antibody levels in this SV/PF-vaccinated group who  
242 possessed pre-existing immunity (refers to as pre-existing immunity group) were compared to  
243 the SV/PF-vaccinated group without pre-existing immunity as shown in Figures 4A and B.  
244 The results showed that the pre-existing immunity group elicited higher total RBD Ig at pre-  
245 dose 2 (V2) and post-dose 2 (V3) than those without pre-existing immunity. However, the  
246 anti-RBD IgG at post-dose 2 (V3) was comparable between both groups.

247 Similarly, there was a subgroup of participants (n=12) in the PF/PF group found to  
248 have been infected with SARS-CoV-2 between vaccination visits 1 and 2 as evidenced by the  
249 seroconversion of anti-N IgG. The baseline characteristics of this subgroup was shown in  
250 Table 1. This group was excluded from the immunogenicity analysis as they presumably had  
251 asymptomatic or unrecognized COVID-19 infection after receiving the first dose of the  
252 BNT162b2 vaccine. Similarly, all the immunogenicity results were available at the end of the  
253 study and children in this group had received the second dose BNT162b2 vaccine. Antibody  
254 levels in this PF/PF-vaccinated group who had a breakthrough infection (refers to as the  
255 breakthrough group) were compared to the PF/PF-vaccinated group without breakthrough  
256 infection as shown in Figure 4C and D. The results showed that the breakthrough group  
257 possessed higher levels of total RBD Ig and anti-RBD IgG than the non-breakthrough group  
258 at pre-dose 2 but not at post-dose 2.

### 259 **3.5 Neutralizing activity against wild-type and Omicron BA.2 using sVNT**

260 Neutralizing activities against wild-type SARS-CoV-2 after two-dose or three-dose  
261 vaccination was above 99% and similar among all groups (Figure 5A). However, following  
262 the second dose vaccination, the homologous PF/PF group possessed higher neutralizing  
263 activities against the Omicron BA.2 variant compared to the heterologous SV/PF group ( $p <$

264 0.001) (Figure 5B). In addition, the three-dose vaccinated group (SP/SP/PF) also elicited  
265 higher neutralizing activities against the Omicron BA.2 variant compared to the heterologous  
266 SV/PF group ( $p < 0.001$ ).

#### 267 **4. Discussion**

268 In this study, we evaluated the extent of binding and neutralizing antibody responses  
269 to the two-dose BNT162b2 regimen and the heterologous CoronaVac followed by the  
270 BNT162b2 vaccine regimen in children between 5-11 years. In addition, we also evaluated  
271 the antibody response after a BNT162b2 vaccine as a booster dose in pediatric individuals  
272 who had received two-dose vaccination (priming) with the inactivated BBIBP-CorV vaccine  
273 regimen. Our study found that at one month post two-dose or three-dose vaccination, children  
274 vaccinated with the two-dose BNT162b2 regimen, the heterologous regimen, and the two-  
275 dose BBIBP-CorV followed by BNT162b2 regimen elicited similar levels of anti-RBD IgG.  
276 All vaccinated groups elicited neutralizing activities against wild-type and Omicron BA.2  
277 variants of SARS-CoV-2 after completion of two-dose or three-dose vaccination. However,  
278 neutralizing activities as determined by percent inhibitions against the Omicron BA.2 variant  
279 were lower than that toward the ancestral strain. Furthermore, the two-dose BNT162b2 and  
280 two-dose BBIBP-CorV followed by BNT162b2 groups elicited higher neutralizing activities  
281 against Omicron BA.2 variant than the CoronaVac/BNT162b2 group.

282 Regarding the two-dose vaccine regimen in children, the real-world effectiveness of  
283 the two-dose CoronaVac or BNT162b2 vaccine regimen amidst the Omicron variant outbreak  
284 showed comparable results. A study in Chile demonstrated that the effectiveness of the two-  
285 dose CoronaVac regimen in children 3-5 years of age was 38.2% against symptomatic  
286 COVID-19, 64.6% against hospitalization, and 69.0% against ICU admission.<sup>17</sup> Similarly,  
287 vaccine effectiveness against hospitalization during the Omicron predominance in children 5  
288 to 11 years old elicited by two doses of BNT162b2 was 68%.<sup>18</sup> Although the present study

289 did not evaluate the effectiveness, the immunogenicity results showed that neutralizing  
290 activities against Omicron BA.2 variant and total RBD Ig in the two-doses BNT162b2 group  
291 administered 8 weeks apart were higher than the heterologous CoronaVac/BNT162b2  
292 administered at 4 weeks apart. Previous studies on adenoviral-vectored and mRNA COVID-  
293 19 vaccine showed that increased dosing intervals improved the vaccine immunogenicity and  
294 effectiveness.<sup>8,19</sup> Similarly, the extended dosing interval of the CoronaVac/BNT162b2 mix-  
295 and-match strategy also showed improved immunogenicity in adults.<sup>9</sup> In Thailand, two doses  
296 of the BNT162b2 vaccine were administered 8 weeks apart, instead of 3 weeks apart as  
297 recommended by the Advisory Committee on Immunization Practices (ACIP),<sup>20</sup> due to the  
298 limited vaccine supply and improved immunogenicity. Nevertheless, the  
299 CoronaVac/BNT162b2 regimen administered 4 weeks apart was recommended. Due to the  
300 lower immunogenicity profile of CoronaVac/BNT162b2, it is worth noting that the  
301 CoronaVac/BNT162b2-vaccinated group should be prioritized for the third dose booster.

302         Several studies in adults showed that heterologous boosters (mRNA vaccine as the  
303 third dose in inactivated COVID-19 vaccine-primed individuals) could enhance antibody  
304 response against the emerging Omicron variant.<sup>12,21</sup> In this study, we evaluated the  
305 immunogenicity after the BNT162b2 booster in BBIBP-CorV-primed individuals 1-3 months  
306 prior and found that the boosted children can elicit neutralizing antibody response against  
307 Omicron BA.2 variant similar to those elicited by two-dose BNT162b2. Our previous study  
308 found that longer interval between primary doses of CoronaVac and booster (i.e., 6 months)  
309 could enhance the total Ig and anti-RBD IgG responses compared to the short interval booster  
310 (i.e., 3 months).<sup>12</sup> Nevertheless, the present study chose the short interval for BBIBP-CorV-  
311 primed individuals to receive a booster because Omicron-specific anti-RBD IgG elicited by  
312 the two-dose inactivated vaccine were low at 3 months after second dose, and get boosted  
313 significantly after an mRNA vaccine as the third (booster) dose.<sup>21</sup> Thus, the heterologous

314 mRNA booster in children primed with inactivated vaccine regimen should be recommended  
315 to increase protection against the emerging Omicron variant. although a longer interval  
316 between the second and the third dose could stimulate higher antibody responses.

317 All COVID-19 vaccines administered as primary or booster doses in this study had  
318 acceptable reactogenicity with mild to moderate AEs that generally resolved within a few  
319 days after vaccination. The adverse events reported herein were similar to those of pain,  
320 myalgia, and fever described in the previous studies.<sup>2, 22</sup>

321 Nearly one-third of the participants in the CoronaVac/BNT162b2 group had been  
322 exposed to the SARS-CoV-2 virus prior to enrollment. This was detected by seropositivity of  
323 anti-nucleocapsid (N) IgG or total RBD Ig at baseline. This study showed that total RBD Ig  
324 are higher in previously infected vaccinees than in SARS-CoV-2 naïve subjects following the  
325 first dose of the CoronaVac vaccination and at one month post-second dose (BNT162b2)  
326 vaccination. Our findings are in line with a study in adults showing that previously infected  
327 individuals who received a booster COVID-19 vaccine elicited higher neutralizing antibodies  
328 compared to the infection alone or vaccine alone.<sup>23</sup> Regarding the two-dose BNT162b2  
329 groups, there was a long waiting time (8 weeks) between the first and second doses of the  
330 BNT162b2 vaccine. Thus, nearly one-third of the participants in the two-dose BNT162b2  
331 group had breakthrough infection after receipt of the first dose of the BNT162b2 vaccine as  
332 determined by seroconversion of anti-N IgG. Similarly, at visit 2 (post one dose + natural  
333 infection), breakthrough infection vaccinees had anti-RBD IgG and total RBD Ig higher than  
334 in SARS-CoV-2 naïve subjects immunized with one-dose BNT162b2 vaccine, but this  
335 difference disappeared after the second dose vaccine. This is also in agreement with a  
336 previous study in adults which showed that previously infected vaccinees who received 2  
337 doses mRNA vaccine elicited higher Omicron BA.1-specific neutralizing antibodies similar

338 to the triple-vaccinated subjects, but higher than SARS-CoV-2 naïve subjects who received 2  
339 doses mRNA vaccine.<sup>24</sup>

340 Potential limitations of our study may be attributed to the loss of some participants  
341 from the final immunogenicity analysis due to the peak of the SRAS-CoV-2 outbreak in  
342 Bangkok during March to April 2022. The BNT162b2 vaccine was in multiple-dose vials  
343 which needed to be administered in a short period. The time limit of keeping opened multi-  
344 dose vials made the randomization not feasible in our study. As of May 2022, there was a  
345 recommendation from the Centers for Disease Control and Prevention that children who  
346 receive two-dose BNT162b2 should get a BNT162b2 booster. Thus, additional studies on the  
347 immunogenicity and efficacy of the third dose (booster) in two-dose BNT162b2 or  
348 heterologous CoronaVac/BNT162b2-primed children should be further investigated.

## 349 **5. Conclusions**

350 Local and systemic AE which occurred within 7 days after vaccination were mild to  
351 moderate and well-tolerated. The heterologous, CoronaVac vaccine followed by the  
352 BNT162b2 vaccine, regimen elicited lower neutralizing activities against the emerging  
353 Omicron BA.2 variant than the two-dose mRNA regimen. A third dose (booster) mRNA  
354 vaccine should be prioritized for this group.

355 **Acknowledgments:** We would like to thank all Center of Excellence in Clinical Virology  
356 personnel and all participants for contributing to and supporting this project. This research  
357 was financially supported by the Health Systems Research Institute (HSRI), National  
358 Research Council of Thailand (NRCT), the Center of Excellence in Clinical Virology,  
359 Chulalongkorn University, and King Chulalongkorn Memorial Hospital, and partially  
360 supported by the Second Century Fund (C2F) of Sitthichai Kanokudom, Chulalongkorn  
361 University.



362 **Author Contributions:** Conceptualization, N.W., S.K. (Sitthichai Kanokudom),  
363 N.S.(Nungruthai Suntronwong), P.N. and Y.P.; data curation, N.W., S.K. (Sitthichai  
364 Kanokudom), N.S. (Nungruthai Suntronwong), S.A., R.Y., D.S., T.T. (Thaksaporn  
365 Thatsanatorn) and N.S. (Natthinee Sudhinaraset); formal analysis, N.W., S.K. (Sitthichai  
366 Kanokudom) and H.P.; methodology, S.K. (Sitthichai Kanokudom), J.C., P.V., S.K. (Sirapa  
367 Klinfueng), T.T (Thanunrat Thongmee), R.A. and N.K.; project administration, Y.P.;  
368 writing—original draft, N.W., S.K. (Sitthichai Kanokudom); writing—review and editing,  
369 N.W., S.K. (Sitthichai Kanokudom) and Y.P. All authors have read and agreed to the  
370 published version of the manuscript.

371 **Funding:** This research was financially supported by the Health Systems Research Institute  
372 (HSRI), National Research Council of Thailand (NRCT), the Center of Excellence in Clinical  
373 Virology, Chulalongkorn University, and King Chulalongkorn Memorial Hospital, and  
374 partially supported by the Second Century Fund (C2F) of Sitthichai Kanokudom,  
375 Chulalongkorn University.

376 **Institutional Review Board Statement:** The study protocol was approved by the  
377 Institutional Review Board (IRB), Faculty of Medicine, Chulalongkorn University (IRB  
378 number 059/65). This trial was registered in the Thai Clinical Trials Registry  
379 (TCTR20220212001).

380 **Informed Consent Statement:** Informed consent was obtained from parents or legal  
381 guardians before participant enrollment. The study was conducted according to the  
382 Declaration of Helsinki and the Good Clinical Practice Guidelines (ICH-GCP) principles.

383 **Data Availability Statement:** The datasets generated and analyzed during the current study  
384 are available from the corresponding author upon reasonable request.

385 **Conflicts of Interest:** The authors declare no conflict of interest.

386 **References**

- 387 1. The World Health Organization (WHO) Coronavirus (COVID-19) Dashboard.  
388 Accessed on 10 October 2022. Available from <https://covid19.who.int/>
- 389 2. Walter EB, Talaat KR, Sabharwal C, et al. Evaluation of the BNT162b2 Covid-19  
390 Vaccine in Children 5 to 11 Years of Age. *N Engl J Med.* 2022;386:35-46.
- 391 3. The United States Food and Drug administration. Accessed on 10 October 2022.  
392 Available from [https://www.fda.gov/news-events/press-announcements/fda-takes-key-action-](https://www.fda.gov/news-events/press-announcements/fda-takes-key-action-fight-against-covid-19-issuing-emergency-use-authorization-first-covid-19)  
393 [fight-against-covid-19-issuing-emergency-use-authorization-first-covid-19](https://www.fda.gov/news-events/press-announcements/fda-takes-key-action-fight-against-covid-19-issuing-emergency-use-authorization-first-covid-19)
- 394 4. Khemiri H, Ayouni K, Triki H, et al. SARS-CoV-2 infection in pediatric population  
395 before and during the Delta (B.1.617.2) and Omicron (B.1.1.529) variants era. *Virology.*  
396 2022;19:144.
- 397 5. Han B, Song Y, Li C, et al. Safety, tolerability, and immunogenicity of an inactivated  
398 SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind,  
399 randomised, controlled, phase 1/2 clinical trial. *Lancet Infect Dis.* 2021;21:1645-53.
- 400 6. Xia S, Zhang Y, Wang Y, et al. Safety and immunogenicity of an inactivated COVID-  
401 19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind,  
402 controlled, phase 1/2 trial. *Lancet Infect Dis.* 2022;22:196-208.
- 403 7. Hause AM, Baggs J, Marquez P, et al. COVID-19 Vaccine Safety in Children Aged  
404 5-11 Years - United States, November 3-December 19, 2021. *MMWR Morb Mortal Wkly*  
405 *Rep.* 2021;70:1755-60.
- 406 8. Grunau B, Goldfarb DM, Asamoah-Boaheng M, et al. Immunogenicity of Extended  
407 mRNA SARS-CoV-2 Vaccine Dosing Intervals. *Jama.* 2022;327:279-81.
- 408 9. Wanlapakorn N, Yorsaeng R, Phowatthanasathian H, Suntronwong N, Kanokudom S,  
409 Sudhinaraset N, Poovorawan Y. Immunogenicity of heterologous prime/boost inactivated and

410 mRNA COVID-19 vaccine. medRxiv 2021.11.20.21266644; doi:

411 <https://doi.org/10.1101/2021.11.20.21266644>

412 10. Cele S, Jackson L, Khoury DS, et al. Omicron extensively but incompletely escapes

413 Pfizer BNT162b2 neutralization. *Nature*. 2022;602:654-6.

414 11. Wanlapakorn N, Suntronwong N, Kanokudom S, et al. Immunogenicity of the

415 BNT162b2 COVID-19 vaccine as a third dose (booster) following two doses of different

416 primary series regimens in Thailand. *Pathog Glob Health*. 2022:1-3.

417 12. Assawakosri S, Kanokudom S, Suntronwong N, et al. Neutralizing Activities against

418 the Omicron Variant after a Heterologous Booster in Healthy Adults Receiving Two Doses of

419 CoronaVac Vaccination. *J Infect Dis*. 2022;jjac092.

420 13. Chansaenroj J, Suntronwong N, Kanokudom S, et al. Immunogenicity following two

421 doses of the BBIBP-CorV vaccine and a third booster dose with a viral vector and mRNA

422 COVID-19 vaccines against Delta and Omicron variants in prime immunized adults with two

423 doses of the BBIBP-CorV vaccine. *Vaccines (Basel)*. 2022;10.

424 14. Shaw RH, Stuart A, Greenland M, et al. Heterologous prime-boost COVID-19

425 vaccination: initial reactogenicity data. *Lancet*. 2021;397:2043-6.

426 15. Wanlapakorn N, Suntronwong N, Phowatthanasathian H, et al. Safety and

427 immunogenicity of heterologous and homologous inactivated and adenoviral-vectored

428 COVID-19 vaccine regimens in healthy adults: a prospective cohort study. *Hum Vaccin*

429 *Immunother*. 2022;18:2029111.

430 16. Assawakosri S, Kanokudom S, Chansaenroj J, et al. Persistence of immunity against

431 Omicron BA.1 and BA.2 variants following homologous and heterologous COVID-19

432 booster vaccines in healthy adults after a two-dose AZD1222 vaccination. *Int J Infect Dis*.

433 2022;122:793-801.

- 434 17. Jara A, Undurraga EA, Zubizarreta JR, et al. Effectiveness of CoronaVac in children  
435 3-5 years of age during the SARS-CoV-2 Omicron outbreak in Chile. *Nat Med*.  
436 2022;28:1377-80.
- 437 18. Price AM, Olson SM, Newhams MM, et al. BNT162b2 Protection against the  
438 Omicron Variant in Children and Adolescents. *N Engl J Med*. 2022;386:1899-909.
- 439 19. Voysey M, Costa Clemens SA, Madhi SA, et al. Single-dose administration and the  
440 influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1  
441 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. *Lancet*.  
442 2021;397:881-91.
- 443 20. Woodworth KR, Moulia D, Collins JP, et al. The Advisory Committee on  
444 Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19  
445 Vaccine in Children Aged 5-11 Years - United States, November 2021. *MMWR Morb*  
446 *Mortal Wkly Rep*. 2021;70:1579-83.
- 447 21. Zuo F, Abolhassani H, Du L, et al. Heterologous immunization with inactivated  
448 vaccine followed by mRNA-booster elicits strong immunity against SARS-CoV-2 Omicron  
449 variant. *Nat Commun*. 2022;13:2670.
- 450 22. Puthanakit T, Nantanee R, Jaru-Ampornpan P, et al. Heterologous prime-boost of  
451 SARS-CoV-2 inactivated vaccine and mRNA BNT162b2 among healthy Thai adolescents.  
452 *Vaccine X*. 2022;12:100211.
- 453 23. Cheng SMS, Mok CKP, Leung YWY, et al. Neutralizing antibodies against the  
454 SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or  
455 BNT162b2 vaccination. *Nat Med*. 2022;28:486-9.
- 456 24. Trombetta CM, Piccini G, Pierleoni G, et al. Immune response to SARS-CoV-2  
457 Omicron variant in patients and vaccinees following homologous and heterologous  
458 vaccinations. *Commun Biol*. 2022;5:903.

459 **Table Legends**460 **Table 1.** Demographics and characteristics of the enrolled children (5-11 years).

Group	Participants eligible for final immunogenicity analysis			Participants who had pre-existing antibody	Participants who had seroconversion of anti-N IgG
	SV/PF	PF/PF	SP/SP/PF	SV/PF ¥	PF/PF §
<b>Total</b>	27	30	56	11	12
<b>Sex, Female/total (%)</b>	12/27 (44.4)	16/30 (53.3)	27/56 (48.2)	6/11 (54.5)	10/12 (83.3)
<b>Mean age in year (SD)</b>	7.4 (2.2)	6.2 (1.1)	7.8 (1.6)	6.3 (1.6)	6.8 (1.8)
<b>No comorbidity (%)</b>	24/27 (88.9)	27/30 (90.0)	48/56 (85.7)	11/11 (100)	12/12 (100)
<b>Underlying diseases (%)</b>					
<b>Allergy</b>	2/27 (7.4)	2/30 (6.7)	6/56 (10.7)	-	-
<b>Asthma</b>	-	1/30 (3.3)	-	-	-
<b>Autism spectrum disorder</b>	-	-	1/56 (1.8)	-	-
<b>Obstructive sleep apnea</b>	1/27 (3.7)	-	-	-	-
<b>Thalassemia trait</b>	-	-	1/56 (1.8)	-	-
<b>Time interval between first and second dose</b>	30.2 (28-41)	57.4 (57-67)	22.9 (21-82)	58.0 (57-67)	58.2 (57-67)
<b>Mean (range), days</b>					
<b>Time interval between second dose and blood sampling</b>	29.3 (27-37)	31.0 (24-46)	-	32.0 (27-36)	32.0 (27-36)
<b>Mean (range), days</b>					
<b>Time interval between second dose and third dose</b>	-	-	61.0 (27-167)	-	-
<b>Mean (range), days</b>					
<b>Time interval between third dose and blood sampling</b>	-	-	31.0 (29-36)	-	-
<b>Median (range), days</b>					

461 ¥ refers to the children who had pre-existing antibody before receipt of 1<sup>st</sup> dose of CoronaVac.462 § refers to the children who had seroconversion of anti-N IgG before receipt of 2<sup>nd</sup> dose of BNT162b


463

464

465

466

467


468 **Figure Legends**

469

470 **Figure 1. Study flow diagram of enrolled children (5-11 years) for final vaccine**  
 471 **immunogenicity analysis.** Unvaccinated children were enrolled to receive either  
 472 heterologous CoronaVac/BNT162b2 (SV/PF) or homologous BNT162b2/BNT162b2 (PF/PF)  
 473 regimen. In addition, the two-dose BBIBP-CorV-primed children were enrolled to receive the  
 474 BNT162b2 as a third dose (SP/SP/PF). Sera were collected at pre-dose 1 (V1), pre-dose 2  
 475 (V2), post-dose 2 (V3), and post-dose 3 (V4), respectively. Children who contracted COVID-  
 476 19 or had evidence of infection as determined by anti-N IgG seroconversion were excluded  
 477 from the final vaccine immunogenicity analysis.


A

## First dose




B

## Second dose



478

479 **Figure 2.** Forest plot showing the percentages of solicited local and systemic adverse events  
 480 (AEs) and the risk differences with 95% confidence intervals (95% CI) in pediatric  
 481 participants with any grade AEs across 7 days after vaccination. The AEs of first dose  
 482 vaccination (A) and second dose vaccination (B) between heterologous SV/PF regimen and  
 483 homologous PF/PF regimen were compared. SV and PF refer to CoronaVac and BNT162b2,  
 484 respectively.



485

486 **Figure 3. Binding antibody specific for SARS-CoV-2 in vaccinated children (5-11 years).**

487 A) Total immunoglobulin specific to the receptor-binding domain (RBD) (Total RBD Ig)

488 (U/mL) and B) anti-RBD IgG (BAU/mL) of the heterologous CoronaVac/BNT1612b2

489 (referred to as SV/PF), homologous BNT1612b2 (referred to as PF/PF), and third dose of

490 BNT162b2 in two-dose BBIBP-CorV-primed (refers to SP/SP/PF) groups. For both graphs

491 the intervals of reported immunological values are as follows: on the day of the first dose

492 (V1; pre-dose 1), 4 and 8 weeks later for SV/PF and PF/PF groups, respectively (V2; pre-

493 dose 2), 4 weeks after two-dose completion in the SV/PF and PF/PF groups and 1-3 months

494 after two-dose completion in the SP/SP/PF group (V3; post-dose 2), and 4 weeks after three-

495 dose completion in the SP/SP/PF group (V4; Post-dose 3). Data points are the reciprocals of

496 the individual. The gray area indicates the seronegativity of total RBD Ig (<0.8 U/mL) or


497 anti-RBG IgG (<7.1 BAU/mL). Lines indicate geometric means and bars indicate 95%

498 confidence intervals (95%CI). A pairwise comparisons display geometric mean ratio (GMR)

499 and significant values including p <0.05 (\*), p <0.001 (\*\*\*) and no statistical significance

500 (ns).





501

502 **Figure 4. Binding antibody specific for SARS-CoV-2 classified by immunity status. A)**

503 Total immunoglobulin specific to the receptor-binding domain (RBD) (Total RBD Ig)

504 (U/mL) and B) anti-RBD IgG (BAU/mL) of the heterologous CoronaVac/BNT1612b2

505 (referred to as SV/PF) group classified by presence or absence of pre-existing immunity at

506 baseline. C) Total RBD Ig (U/mL) and D) Anti-RBD IgG (BAU/mL) of the homologous

507 BNT1612b2 (referred to as PF/PF) group classified by breakthrough or non-breakthrough


508 infection. For all graphs the intervals of reported immunological values are as follows: on the

509 day of the first dose (V1; pre-dose 1), 4 and 8 weeks later for SV/PF and PF/PF groups,

510 respectively, (V2; pre-dose 2), and 4 weeks after two-dose completion (V3; post-dose 2).

511 Data points are the reciprocals of the individual. The gray area indicates the seronegativity of

512 total RBD Ig (<0.8 U/mL) or anti-RBG IgG (<7.1 BAU/mL). Lines indicate geometric  
 513 means and bars indicate 95% confidence intervals (95%CI). A pairwise comparisons display  
 514 geometric mean ratio (GMR) and significant values including  $p < 0.01$  (\*\*),  $p < 0.001$  (\*\*\*)  
 515 and no statistical significance (ns).



516  
 517 **Figure 5.** Neutralizing activity against the A) wild-type and B) BA.2 Omicron variant at one  
 518 month after a two-dose or three-dose vaccination. Lines indicate median percent inhibition  
 519 and the error bar indicates the interquartile range (IQR). The gray area indicates the  
 520 seronegativity of neutralizing activity of the wild-type (<35%) and BA.2 Omicron variant  
 521 (<30%). A pairwise comparisons display statistical significance,  $p < 0.001$  (\*\*\*)  
 522  
 523  
 524  
 525  
 526  
 527